Blog

Two North Carolina cities have been part of medical history in the making. Duke Cancer Institute in Durham and Sarah Cannon Family Medicine in Asheville participated in PATHFINDER 2, one of the largest clinical trials of its kind, testing a new blood test designed to detect dozens of types of... Continue Reading

Join NCLifeSci for an April 23 informational webinar, where our partners at Marsh McLennan will walk you through the ins and outs of the health plan. REGISTER HERE >> The association health plan for NCLifeSci member companies will be delayed a year after Blue Cross Blue Shield of NC paused... Continue Reading

The NC Life Sciences Organization is profoundly concerned about the recently announced 100% tariff on brand-name pharmaceuticals made by President Donald Trump. This policy, if implemented, would have severe and far-reaching negative consequences for patients, the life sciences industry and the... Continue Reading

Sen. Thom Tillis (R-NC) and Sen. Ted Budd (R-NC) have joined their colleague in North Carolina's House delegation in recognizing the harm caused by the Inflation Reduction Act's penalty for small-molecule drug. They have introduced the bipartisan Ensuring Pathways to Innovative Cures Act in the... Continue Reading

Rep. Greg Murphy, M.D., (R-NC); Rep. Don Davis (D-NC); and Rep. Richard Hudson (R-NC) have recognized the harm in penalizing small-molecule drug and have reintroduced the bipartisan Ensuring Pathways to Innovative Cures Act to be considered by the 119th Congress. The EPIC Act simply equalizes the... Continue Reading

Thanks in no small part to the support of North Carolina’s Congressional delegation, multicancer early detection testing now will be available to active-duty military, National Guard and Reserve members, retirees and their families. North Carolina has one of the largest active-duty... Continue Reading

The North Carolina Life Sciences Organization strongly values the role university research plays in driving the creation of new life sciences companies, groundbreaking medicines and transformative treatments. We recognize that North Carolina's vibrant life sciences ecosystem is built upon a... Continue Reading

A new report from the North Carolina State Treasurer found North Carolina hospitals use the federal 340B program to profit at the expense of patients, teachers and state employees. Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to... Continue Reading

A 2022 tax rule requiring the amortization of research and development expenses has created significant challenges for many life sciences startups and small businesses. Previously, grant money received by these companies and spent on R&D could be deducted immediately in full, but the new rule... Continue Reading

The small red bump on my son's hand looked at first like a bug bite. But when the hand swelled to the point of immobility and we took him to the doctor, the diagnosis was MRSA, an infection from a type of staph bacteria resistant to the family of antibiotics usually prescribed as... Continue Reading

A new study estimates that there would be 237 fewer FDA approvals of new medicines over the next decade and 1.1 million lost jobs if proposals to expand government-mandated drug pricing policies are implemented. The policies include allowing Medicare to set prices for specific drugs five years... Continue Reading

The rarest day on the calendar is the one that does not even occur in every year: February 29. In 2008, this was designated as Rare Disease Day and since then, the last day of February has been an opportunity to draw attention to, honor and support people living with these... Continue Reading